
Novartis AG
NVSHealthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
Financials
Financial Snapshot
Market Cap
$307.00B
Enterprise Value
$345.79B
Revenue (TTM)
$56.31B
Net Income (TTM)
$10.03B
Cash & Investments
$8.97B
Net Cash
-$39.34B
Free Cash Flow (TTM)
$14.84B
Operating CF (TTM)
$17.32B
Debt/Equity
1.30
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $7.78B | $9.48B | $15.96B | $11.45B | $11.56B | $28.11B | $18.61B | $13.96B | $13.35B | $11.59B | $8.97B | |
| Operating Cash Flow | $11.47B | $12.62B | $14.27B | $13.63B | $13.65B | $15.07B | $14.24B | $14.46B | $17.62B | $19.24B | $17.32B | |
| Free Cash Flow | $8.60B | $9.88B | $10.92B | $11.37B | $11.06B | $12.52B | $12.00B | $11.71B | $13.80B | $17.69B | $14.84B | |
| Capital Expenditure | -$2.88B | -$2.75B | -$3.35B | -$2.26B | -$2.58B | -$2.56B | -$2.24B | -$2.75B | -$3.81B | -$1.56B | -$2.48B | |
| Financing Cash Flow | -$5.31B | -$7.73B | -$4.24B | -$13.63B | -$2.21B | -$16.26B | -$20.56B | -$14.28B | -$11.74B | -$14.94B | $797.2M |
R&D Spending
R&D (TTM)
$13.49B
R&D Intensity
24.0%
R&D Growth vs Prior
+25.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.44B | $43.40B | $46.10B | $48.68B | $49.90B | $43.97B | $43.46B | $46.66B | $51.72B | $54.81B | $56.31B | |
| R&D Expense | $9.04B | $8.39B | $8.49B | $9.40B | $8.98B | $8.64B | $9.17B | $11.37B | $10.02B | $10.74B | $13.49B | |
| R&D % of Revenue | 18.3% | 19.3% | 18.4% | 19.3% | 18.0% | 19.7% | 21.1% | 24.4% | 19.4% | 19.6% | 24.0% | |
| SG&A | $14.19B | $12.46B | $13.72B | $14.37B | $14.20B | $12.83B | $12.19B | $12.52B | $12.57B | $13.31B | $12.90B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.44B | $43.40B | $46.10B | $48.68B | $49.90B | $43.97B | $43.46B | $46.66B | $51.72B | $54.81B | $56.31B | |
| Cost of Revenue | $17.52B | $13.63B | $14.51B | $14.43B | $15.12B | $11.73B | $11.58B | $12.47B | $12.83B | $13.69B | $14.29B | |
| Gross Profit | $31.92B | $29.77B | $31.59B | $34.25B | $34.78B | $32.24B | $31.88B | $34.19B | $38.90B | $41.12B | $42.02B | |
| R&D | $9.04B | $8.39B | $8.49B | $9.40B | $8.98B | $8.64B | $9.17B | $11.37B | $10.02B | $10.74B | $13.49B | |
| SG&A | $14.19B | $12.46B | $13.72B | $14.37B | $14.20B | $12.83B | $12.19B | $12.52B | $12.57B | $13.31B | $12.90B | |
| Operating Income | $8.27B | $8.70B | $8.40B | $9.09B | $10.15B | $10.06B | $7.95B | $9.77B | $14.54B | $17.07B | $14.33B | |
| Interest Expense | $729.0M | $802.0M | $973.2M | $902.9M | $921.0M | $905.0M | $834.6M | $876.1M | $1.04B | $1.19B | $1.58B | |
| Pretax Income | $7.82B | $9.10B | $14.10B | $8.94B | $9.88B | $24.53B | $7.18B | $9.12B | $13.64B | $16.44B | $12.65B | |
| Net Income | $6.71B | $7.70B | $12.61B | $11.73B | $8.07B | $24.02B | $6.96B | $14.85B | $11.94B | $14.06B | $10.03B | |
| EPS (Diluted) | 2.80 | 3.25 | 5.38 | 3.08 | 3.52 | 10.63 | 3.17 | 7.10 | 5.87 | 7.19 | 5.24 | |
| EBITDA | $14.57B | $14.59B | $20.24B | $15.62B | $17.21B | $30.91B | $14.68B | $18.25B | $20.71B | $22.99B | $21.78B | |
| Shares Out. (M) | 2400.00 | 2371.00 | 2344.00 | 2319.00 | 2296.00 | 2260.00 | 2197.00 | 2092.00 | 2035.00 | 1955.00 | 1905.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.01B | $8.86B | $13.27B | $11.11B | $9.66B | $12.41B | $7.52B | $13.39B | $11.46B | $11.44B | $8.87B | |
| Short-Term Investments | $770.0M | $625.0M | $2.69B | $334.0M | $1.91B | $15.71B | $11.10B | $569.0M | $1.89B | $155.0M | $105.0M | |
| Total Current Assets | $24.93B | $28.21B | $35.56B | $29.50B | $29.67B | $45.72B | $36.91B | $30.48B | $29.70B | $30.46B | $28.75B | |
| Total Assets | $130.12B | $133.08B | $145.56B | $118.41B | $132.19B | $131.79B | $117.45B | $99.94B | $102.25B | $115.57B | $117.15B | |
| Total Current Liabilities | $22.21B | $23.40B | $29.61B | $28.26B | $33.06B | $30.21B | $28.66B | $26.39B | $28.69B | $27.28B | $32.52B | |
| Long-Term Debt | $17.90B | $23.22B | $22.47B | $20.35B | $26.26B | $22.90B | $20.24B | $18.44B | $21.37B | $29.59B | $36.70B | |
| Total Liabilities | $55.23B | $58.85B | $66.87B | $62.86B | $75.52B | $63.97B | $58.03B | $53.20B | $58.12B | $69.02B | $79.58B | |
| Stockholders' Equity | $74.83B | $74.17B | $78.61B | $55.47B | $56.60B | $67.66B | $59.34B | $46.67B | $44.05B | $46.13B | $37.23B | |
| Retained Earnings | $81.15B | $77.64B | $82.19B | $59.27B | $57.16B | $70.99B | $63.54B | $49.65B | $46.56B | $44.72B | $39.24B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $11.47B | $12.62B | $14.27B | $13.63B | $13.65B | $15.07B | $14.24B | $14.46B | $17.62B | $19.24B | $17.32B | |
| Capital Expenditure | -$2.88B | -$2.75B | -$3.35B | -$2.26B | -$2.58B | -$2.56B | -$2.24B | -$2.75B | -$3.81B | -$1.56B | -$2.48B | |
| Free Cash Flow | $8.60B | $9.88B | $10.92B | $11.37B | $11.06B | $12.52B | $12.00B | $11.71B | $13.80B | $17.69B | $14.84B | |
| Investing Cash Flow | -$3.44B | -$3.12B | -$5.59B | -$2.23B | -$13.18B | $4.21B | $1.47B | $5.60B | -$7.51B | -$4.90B | -$18.68B | |
| Financing Cash Flow | -$5.31B | -$7.73B | -$4.24B | -$13.63B | -$2.21B | -$16.26B | -$20.56B | -$14.28B | -$11.74B | -$14.94B | $797.2M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $27.1M | $18.0M | |
| Repurchase of Stock | -$1.11B | -$5.49B | -$2.04B | -$5.53B | -$2.84B | -$3.06B | -$10.65B | -$8.72B | -$8.33B | -$9.26B | -$6.25B | |
| Net Debt Issuance | $2.06B | $4.10B | $4.18B | -$4.96B | $7.07B | -$5.67B | -$2.58B | -$1.94B | $4.39B | $2.72B | $16.33B | |
| Stock Based Comp. | $671.0M | $683.0M | $759.0M | $758.0M | $738.0M | $700.0M | $791.0M | $865.0M | $1.04B | $0.00 | $570.0M | |
| Net Change in Cash | $2.33B | $1.85B | $4.41B | -$2.16B | -$1.45B | $2.75B | -$4.89B | $5.88B | -$1.93B | -$24.0M | -$685.9M |
Dilution Tracker
Shares Outstanding
1889M
5-Year Share Growth
-14.9%
Stock Issuance (TTM)
$18.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2400.00 | 2371.00 | 2344.00 | 2319.00 | 2296.00 | 2260.00 | 2197.00 | 2092.00 | 2035.00 | 1955.00 | 1905.00 | |
| Change vs Prior % | — | -1.2% | -1.1% | -1.1% | -1.0% | -1.6% | -2.8% | -4.8% | -2.7% | -3.9% | -2.6% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $27.1M | $18.0M | |
| Stock Repurchase | -$1.11B | -$5.49B | -$2.04B | -$5.53B | -$2.84B | -$3.06B | -$10.65B | -$8.72B | -$8.33B | -$9.26B | -$6.25B | |
| Stock Based Comp. | $671.0M | $683.0M | $759.0M | $758.0M | $738.0M | $700.0M | $791.0M | $865.0M | $1.04B | $0.00 | $570.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 64.6% | 68.6% | 68.5% | 70.4% | 69.7% | 73.3% | 73.4% | 73.3% | 75.2% | 75.0% | 74.6% | |
| Operating Margin % | 16.7% | 20.0% | 18.2% | 18.7% | 20.3% | 22.9% | 18.3% | 20.9% | 28.1% | 31.2% | 25.5% | |
| Net Margin % | 13.6% | 17.7% | 27.4% | 24.1% | 16.2% | 54.6% | 16.0% | 31.8% | 23.1% | 25.6% | 17.8% | |
| EBITDA Margin % | 29.5% | 33.6% | 43.9% | 32.1% | 34.5% | 70.3% | 33.8% | 39.1% | 40.1% | 41.9% | 38.7% | |
| FCF Margin % | 17.4% | 22.8% | 23.7% | 23.4% | 22.2% | 28.5% | 27.6% | 25.1% | 26.7% | 32.3% | 26.4% | |
| ROE % | 9.0% | 10.4% | 16.0% | 21.1% | 14.3% | 35.5% | 11.7% | 31.8% | 27.1% | 30.5% | 24.2% | |
| ROA % | 5.2% | 5.8% | 8.7% | 9.9% | 6.1% | 18.2% | 5.9% | 14.9% | 11.7% | 12.2% | 8.4% | |
| ROIC % | 6.1% | 6.2% | 6.1% | 7.5% | 7.6% | 8.7% | 7.1% | 11.5% | 15.5% | 15.5% | 14.0% | |
| R&D / Revenue % | 18.3% | 19.3% | 18.4% | 19.3% | 18.0% | 19.7% | 21.1% | 24.4% | 19.4% | 19.6% | 24.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.9% | -12.2% | 6.2% | 5.6% | 2.5% | -11.9% | -1.2% | 7.4% | 10.8% | 6.0% | |
| Gross Profit | -3.2% | -6.7% | 6.1% | 8.4% | 1.5% | -7.3% | -1.1% | 7.2% | 13.8% | 5.7% | |
| Operating Income | -7.9% | 5.2% | -3.4% | 8.1% | 11.7% | -0.9% | -21.0% | 22.9% | 48.9% | 17.4% | |
| Net Income | -62.3% | 14.8% | 63.7% | -7.0% | -31.2% | 197.6% | -71.0% | 113.5% | -19.6% | 17.7% | |
| EPS (Diluted) | -61.6% | 16.1% | 65.5% | -42.8% | 14.3% | 202.0% | -70.2% | 124.0% | -17.3% | 22.5% | |
| Operating Cash Flow | -3.5% | 10.0% | 13.1% | -4.5% | 0.2% | 10.4% | -5.5% | 1.6% | 21.9% | 9.2% | |
| Free Cash Flow | 6.8% | 14.9% | 10.6% | 4.1% | -2.7% | 13.1% | -4.1% | -2.4% | 17.9% | 28.1% | |
| R&D Expense | 1.2% | -7.2% | 1.2% | 10.8% | -4.5% | -3.8% | 6.1% | 24.0% | -11.9% | 7.2% | |
| SG&A Expense | -0.4% | -12.2% | 10.0% | 4.8% | -1.2% | -9.6% | -4.9% | 2.7% | 0.4% | 5.9% | |
| Total Assets | -1.1% | 2.3% | 9.4% | -18.7% | 11.6% | -0.3% | -10.9% | -14.9% | 2.3% | 13.0% | |
| Book Value / Share | -1.9% | 0.5% | 7.2% | -28.5% | 2.6% | 21.5% | -9.9% | -17.4% | -2.9% | 9.8% | |
| Debt | 8.5% | 19.4% | 12.9% | -9.2% | 29.9% | -18.0% | -10.0% | -5.6% | 18.6% | 18.5% | |
| Diluted Shares | -1.6% | -1.2% | -1.1% | -1.1% | -1.0% | -1.6% | -2.8% | -4.8% | -2.7% | -3.9% |
Valuation
P/E (TTM)31.18
10Y Low / Med / High7.73 / 21.42 / 28.72
P/S5.57
10Y Low / Med / High2.93 / 4.22 / 4.88
P/B8.22
10Y Low / Med / High1.94 / 3.60 / 5.79
EV/EBITDA15.39
10Y Low / Med / High6.61 / 12.64 / 14.30
EV/Revenue6.29
10Y Low / Med / High3.27 / 4.64 / 5.34
P/FCF19.96
10Y Low / Med / High14.23 / 16.69 / 18.39
Intrinsic Value Models (per share)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 21.61 | 21.42 | 13.20 | 28.72 | 25.24 | 7.73 | 26.91 | 14.12 | 16.44 | 19.02 | 31.18 | |
| P/S Ratio | 2.93 | 3.80 | 3.61 | 4.22 | 4.08 | 4.22 | 4.31 | 4.49 | 3.80 | 4.88 | 5.57 | |
| P/B Ratio | 1.94 | 2.22 | 2.12 | 3.70 | 3.60 | 2.74 | 3.16 | 4.49 | 4.46 | 5.79 | 8.22 | |
| EV/EBITDA | 11.10 | 12.64 | 9.16 | 14.30 | 13.46 | 6.61 | 14.14 | 12.20 | 10.44 | 12.74 | 15.39 | |
| EV/Revenue | 3.27 | 4.25 | 4.02 | 4.59 | 4.64 | 4.64 | 4.78 | 4.77 | 4.18 | 5.34 | 6.29 |
Analyst Estimates & Quality
Altman Z-Score
3.63
Safe
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $57.19B | $61.01B | $64.79B |
| Net Income | $17.33B | $19.27B | $21.10B |
| EPS | $8.86 | $9.86 | $10.79 |
| # Analysts (EPS) | 6 | 8 | 6 |
Dividends
Dividend/Share (TTM)
$4.51
Dividend Yield
2.78%
Frequency
Annual
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Mar 11, 2026 | Mar 16, 2026 | $4.74 | Annual |
| Mar 12, 2025 | Apr 25, 2025 | $3.99 | Annual |
| Mar 7, 2024 | Apr 19, 2024 | $3.20 | Annual |
| Mar 9, 2023 | Mar 20, 2023 | $3.50 | Annual |
| Mar 8, 2022 | Mar 17, 2022 | $3.33 | Annual |
| Mar 4, 2021 | Mar 15, 2021 | $3.20 | Annual |
| Mar 3, 2020 | Mar 12, 2020 | $3.09 | Annual |
| Mar 4, 2019 | Mar 13, 2019 | $2.57 | Annual |
| Mar 6, 2018 | Apr 25, 2018 | $2.67 | Annual |
| Mar 1, 2017 | Apr 20, 2017 | $2.46 | Annual |
| Feb 24, 2016 | Apr 15, 2016 | $2.47 | Annual |
| Mar 2, 2015 | Apr 20, 2015 | $2.52 | Annual |
| Feb 27, 2014 | Apr 10, 2014 | $2.72 | Annual |
| Feb 26, 2013 | Apr 5, 2013 | $2.27 | Annual |
| Feb 27, 2012 | Apr 5, 2012 | $2.20 | Annual |
| Feb 24, 2011 | Apr 8, 2011 | $2.36 | Annual |
| Mar 2, 2010 | Apr 13, 2010 | $1.95 | Annual |
| Feb 24, 2009 | Apr 6, 2009 | $1.54 | Annual |
| Feb 26, 2008 | Apr 11, 2008 | $1.54 | Annual |
| Mar 6, 2007 | Apr 10, 2007 | $0.97 | Annual |
Revenue Segments
By Product
| Segment | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Top 20 products | $26.95B | $28.65B | $29.92B | $32.66B | $32.14B |
| Rest of portfolio | $7.95B | $9.07B | $9.10B | $9.33B | $9.16B |
| COPD | — | $427.0M | — | — | — |
| Anti Infectives sold under Sandoz name | — | $784.0M | $694.0M | $707.0M | $777.0M |
| Total anti-infectives net sales | — | — | — | $1.10B | $1.20B |
By Geography
| Segment | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Country of domicile | $852.0M | — | $800.0M | $873.0M | $970.0M |
| FRANCE | $2.71B | $2.44B | $2.44B | $2.52B | $2.26B |
| GERMANY | $4.18B | $4.12B | $4.52B | $4.87B | $4.28B |
| JAPAN | $3.17B | $2.66B | $2.80B | $2.68B | $2.21B |
| Other countries | $22.17B | — | $19.04B | $20.81B | $20.05B |
| UNITED STATES | $17.56B | $16.28B | $16.48B | $16.82B | $17.65B |
| CHINA | — | — | $2.57B | $3.05B | $3.13B |